DrugsControl Media Services

News Detail

US FDA Creates Pathway to Review Tumor Assays Based on Approval of MSK Panel (18-11-2017)

New York, 17 Nov 2017: Memorial Sloan Kettering Cancer Center (MSK) has won the FDA’s first authorization for a first tumor-profiling laboratory-developed test (LDT)—an approval that has led the agency to create a regulatory pathway for reviewing similar assays.

View Details
Source : Genetic Engineering & Biotechnology News

Related News